50 closest statements
by meaning · ranked by similarity · 100 per pageMeaning search returns the 50 nearest statements, then applies your filters.
“Our mission is to significantly impact the clinical disability associated with NI&I diseases with small molecules designed to modulate innate pathways to restore function.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0590% match
“Our mission is to leverage unique insights into protein motion to transform the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of small molecule therapies.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2670% match
“Our mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-03-0769% match
“Our mission is to discover and develop broadly accessible oral therapeutics to treat a wide range of chronic diseases with unmet medical need through advancements in structure-based drug discovery and computational chemistry.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2669% match
“Our mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function to enable patients with these disorders to live fuller and healthier lives.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-04-2368% match
“Our mission is to leverage our unique insights into finding and binding cryptic functional pockets on currently intractable human biology-validated protein targets to discover, develop and commercialize small molecule therapies that can transform the lives of patients suffering from devastating cancers and immune disorders.”In use 2021 – now·1 sighting·SEC Form S-1, filed 2021-06-2568% match
“Our mission is to discover and develop novel therapeutics to improve the lives of patients living with debilitating CNS disorders.”In use 2025 – now·1 sighting·SEC Form S-1/A, filed 2025-10-0667% match
“Our mission is to become a leading pharmaceutical company by pioneering Bicycle molecules as a novel therapeutic modality to treat diseases that are inadequately addressed with existing treatment modalities.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1767% match
“Our mission is to identify, develop, and, directly or through collaborations, bring to market novel products for the treatment of rare and ultra-rare diseases or conditions.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-03-1467% match
“Our mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest unmet medical need – aggressive cancers where current therapies are inadequate.”In use 2016 – now·1 sighting·SEC Form 10-K, filed 2016-02-2967% match
“Our mission is to develop therapeutics that restore healthy immune regulation for patients with severe autoimmune and inflammatory diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1067% match
“Our mission is to deliver significant clinical benefit to patients suffering from disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0467% match
“Our mission is to discover and develop novel therapeutics to address significant medical needs.”In use 2007 – now·1 sighting·SEC Form 10-K, filed 2007-03-1967% match
“Our mission is to develop innovative therapies to address areas of high unmet medical need, initially in RASopathies for NF1.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-3066% match
“Our mission is to transform the lives of patients with chronic IMIDs through the development of oral, safe and effective small molecule product candidates.”In use 2026 – now·1 sighting·SEC Form S-1/A, filed 2026-01-2766% match
“Our mission is to discover and develop novel therapeutic drugs to treat diseases and disorders for which there are no adequate therapies or for which a new drug would represent a significant advancement over the current therapy.”In use 2003 – now·1 sighting·SEC Form 10-K, filed 2003-03-1466% match
“Our mission is to address a broad range of diseases where chronic inflammation and immune dysfunction are primary drivers of pathology.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-3066% match
“Our mission is to develop first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy, or DMD, and other rare disorders.”In use 2020 – now·1 sighting·SEC Form 10-K, filed 2020-03-2766% match
“Our mission is to enable patients with these disorders to live fuller and healthier lives through the discovery and development of transformative therapies that overcome the key limitations of currently available treatments.”In use 2026 – now·1 sighting·SEC Form 424B4, filed 2026-08-1266% match
“Our mission is to discover, develop, and deliver novel, life-transforming therapies to people suffering from rare, severe, and devastating neuromuscular diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0366% match
“Our mission is to develop novel therapeutics to treat rare, chronic, and serious infectious diseases in areas of high unmet medical need.”In use 2022 – now·1 sighting·SEC Form 424B4, filed 2022-03-2865% match
“Our mission is to leverage our unique insights into the chromatin regulatory system to pioneer the discovery, development and commercialization of a new class of therapies that transform the lives of patients suffering from a wide spectrum of diseases with high unmet need.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1165% match
“Our mission is to bring life-changing therapeutics to people living with rare diseases.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-1265% match
“Our mission is to enable patients with these disorders to live fuller and healthier lives through the discovery and development of transformative precision peptide therapies.”In use 2025 – now·1 sighting·SEC Form 424B4, filed 2025-09-2565% match
“Our mission is to advance drug-free neuromodulation therapies that improve patient outcomes and reduce medication burden in complex disorders, while expanding access to effective care for populations with significant unmet needs.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1965% match
“Our mission is to develop and commercialize novel, non-opioid, and non-addictive therapies to safely and effectively address the significant unmet medical need of chronic pain or treat conditions that cause pain.”In use 2021 – now·1 sighting·SEC Form 10-K, filed 2021-03-3065% match
“Our mission is to improve the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of novel protein degraders.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2465% match
“Our mission is to improve patient outcomes in the areas of neurodegenerative and oncological diseases by developing safe and effective cellular therapies that leverage the power of a patient’s immune system.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-10-0865% match
“Our mission is to team with clinicians to advance innovative device therapies that modulate the ANS to meaningfully improve the lives of people with chronic disease.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-1365% match
“Our mission is to develop, license and acquire non-invasive treatments designed to help patients affected by neurological symptoms caused by disease or trauma.”In use 2016 – now·1 sighting·SEC Form 10-K/A, filed 2016-11-0165% match
“Our mission is to discover, develop and commercialize a new class of RNA editing therapies capable of improving the lives of patients with rare and highly prevalent diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1265% match
“Our mission is to provide superior treatment options for complex diseases and disorders to improve the lives of patients by developing innovative new medicines that exploit the unique role of NNRs.”In use 2012 – now·1 sighting·SEC Form 10-K, filed 2012-03-0665% match
“Our mission is to develop and commercialize novel, non-opioid and non-addictive therapies to safely and effectively address the significant unmet medical need of chronic pain.”In use 2019 – now·1 sighting·SEC Form S-1/A, filed 2019-12-2365% match
“Our mission is to address the unmet medical need associated with vector-borne diseases through the development and commercialization of new small molecule therapeutics, focusing on synthetic drugs (made by chemists in labs, excluding biologics) with good safety profiles based on prior clinical studies, in order to reduce cost, risk, and capitalize on existing research.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-3065% match
“Our mission is to discover and develop best- and first-in-class medicines for a broad range of difficult-to-treat diseases in collaboration with our partners.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-04-0865% match
“Our mission is to improve patients’ daily lives and prevent the long-term effects of uncontrolled inflammation that are a consequence of the limitations of existing therapies.”In use 2026 – now·1 sighting·SEC Form S-1, filed 2026-04-1765% match
“Our mission is to develop, register and commercialize safe and effective drugs, with novel mechanisms of action, to meet the major unmet medical needs of patients on a global basis.”In use 2012 – now·1 sighting·SEC Form 10-K, filed 2012-03-1565% match
“Our mission is to translate the promise of gene editing into a broad class of differentiated, transformational medicines for previously untreatable diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0965% match
“Our mission is to improve the lives of patients who suffer from rare diseases for which there are limited or no available treatments, with an initial therapeutic focus on Cirrhosis ascites, patients suffering from AIDS, Cancer and chronic pain, nausea and discomfort associated with chemotherapy and neuropathy.”In use 2017 – now·1 sighting·SEC Form 10-K, filed 2017-11-0665% match
“Our mission is to develop therapeutic drugs designed to treat neurodegenerative diseases, currently focusing on Parkinsonian and other movement disorders.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-08-2864% match
“Our mission is to make a meaningful impact on the lives of patients with cancer and high unmet medical needs by delivering novel, PRAME-directed immunotherapies that provide tangible clinical benefits.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-03-0564% match
“Our mission is to become a global leader in the treatment of rare diseases through commercializing, developing and acquiring novel rare disease products.”In use 2021 – now·1 sighting·SEC Form 424B4, filed 2021-01-1464% match
“Our mission is to discover, develop and commercialize novel and transformative therapies that improve the lives of patients with serious diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-02-2264% match
“Our mission is to develop and commercialize first-in-class medicines based on novel targets to improve patients’ lives.”In use 2022 – now·1 sighting·SEC Form 20-F, filed 2022-03-2464% match
“Our mission is to provide therapeutic relief to those suffering from debilitating rare diseases that have limited or no treatment options to help them live their best possible lives and achieve their full potential.”In use 2024 – now·1 sighting·SEC Form 20-F, filed 2024-04-3064% match
“Our mission is to significantly improve patient outcomes and address areas of high unmet medical need with our nanotechnology-based therapies.”In use 2020 – now·1 sighting·SEC Form 424B4, filed 2020-12-1164% match
“Our mission is to design and deliver next generation immunotherapies for neurodegenerative and neuroinflammatory diseases.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-05-0164% match
“Our mission is to discover new medicines that improve the lives of people facing serious muscle disease.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2664% match
“Our mission is to create disease-modifying neurogenetic medicines by identifying validated targets, advancing multiple therapeutic modalities, and delivering them to the right areas within the central nervous system.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-1164% match
“Our mission is to develop therapeutic products with the potential to address high unmet medical needs by identifying promising clinical-stage candidates and advancing their development to create products that will improve patients’ lives.”In use 2026 – now·1 sighting·SEC Form S-1, filed 2026-08-2164% match
Showing 1–50 of 50